Butterfly Network Inc (BFLY) posted a 5% year-over-year revenue growth for the third quarter of 2025, bringing in $21.5 million, which exceeded the projected $21.22 million, as detailed in a
In spite of these setbacks, Butterfly Network saw its adjusted gross margin rise to 63.9% from the previous year's 60.0%, attributed to higher average selling prices and lower software amortization expenses, as reported by GuruFocus. The company’s cash and cash equivalents stood at $144.2 million as of September 30, 2025, showing a modest increase from earlier periods, according to GuruFocus. Operating expenses climbed to $31.4 million, marking a 6% increase year-over-year, as the company continues to invest in technology and enterprise sales, GuruFocus further noted.
 Butterfly Network maintained its full-year 2025 revenue outlook of $91 million to $95 million and tightened its adjusted EBITDA loss forecast to between $32 million and $35 million, according to GuruFocus. The company reiterated its dedication to innovation, highlighting the development of the P5.1 chip and the forthcoming Apollo AI chip, which is expected to deliver greater processing capabilities and on-device AI, as mentioned in the Yahoo Finance article. Furthermore, Butterfly Network’s AI-powered lung tool, Auto B-line Counter, showed both clinical and financial advantages, such as reducing hospital stays by 30% and saving over $750,000 in costs, as reported by Yahoo Finance.
Nonetheless, the company continues to face obstacles. It cited challenges in enterprise sales as hospitals focus on larger economic issues, and persistent churn in individual subscriptions is impacting software and service revenues, according to Yahoo Finance. The ongoing federal government shutdown could also delay deal closures and regulatory approvals, though these effects are currently limited, Yahoo Finance added.